U.S. biopharma companies are increasingly licensing innovative drug candidates from Chinese firms, fueled by China’s biotech advancements, lower costs, and a surge in available assets, with DealForma data highlighting the trend. This growing shift is reshaping the global biopharma landscape, creating both opportunities for efficiency and concerns about the future of U.S. biotech startups. Read the article here
